Compugen

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Compugen reports Q1 loss, showcases promising cancer immunotherapy approach

Compugen's Q1 2023 performance reflects a strategic focus on capital efficiency and milestone achievement.
Their innovative triple combination approach in cancer immunotherapy shows promise, with encouraging clinical benefits observed.
While managing R&D expenses and translating clinical benefits into marketable products are challenges, opportunities exist in disciplined cash deployment and exploration of biomarkers.
Overall, Compugen's financial discipline, promising clinical data, and strategic focus position them well for future growth in the oncology space.

Compugen (CGEN) reports positive ASCO results and solid financial standing

Compugen (CGEN) showcases promising results in cancer immunotherapy combinations, maintaining a strong financial position despite increased R&D expenses. The company's differentiated approach and focus on milestone achievement through 2024 position it well for future growth, although challenges in enrollment delays and managing expenses persist.

Compugen reports Q3 progress with promising clinical data and partnerships

Compugen's Q3 2023 performance reflects progress in clinical trials and financial stability with a cash balance of $57.5 million.
Strengths lie in innovative drug discovery approaches, successful clinical outcomes, and strategic partnerships.
Challenges include competitive enrollment landscape, cost management, and market acceptance of novel treatments.
Opportunities exist in upcoming data reporting, novel drug targets, and collaborations for future growth and success.

Compugen reports robust earnings and strategic partnerships drive growth

Compugen's Q4 2023 performance reflects strong financial results and notable achievements in clinical advancements and partnerships.
The company's financial stability, strategic focus, and robust pipeline position them well for future growth and innovation.
While facing challenges in clinical trial outcomes and partnership strategies, Compugen has opportunities to drive further growth through data insights and collaborations.

Compugen reports solid Q1 performance, poised for growth in 2024

Compugen's Q1 2024 performance reflects financial stability, operational efficiency, and progress in advancing key drug candidates towards clinical trials, underpinned by a robust AI discovery platform and strategic partnerships.
While challenges like ongoing R&D investments and achieving profitability persist, opportunities in milestone achievements, data readouts, and strategic collaborations position Compugen for future growth and value creation.
Navigating the biopharmaceutical landscape with innovation, financial discipline, and strategic foresight, Compugen stands poised to capitalize on market opportunities, drive pipeline progression, and enhance shareholder value.

Compugen reports Q2 revenue of $6.7M, highlights innovative drug strategies

Compugen's Q2 2024 performance reflects steady revenue generation and prudent financial management. The company's strengths in innovative drug development and strategic collaborations present promising growth opportunities. Addressing challenges in clinical evidence and cash burn will be crucial for sustained success.

Compugen reports solid Q3 earnings, advances promising ovarian cancer therapies

Compugen's strong financial position, promising clinical data on multiple therapies, and strategic focus on ovarian cancer treatment advancements position the company for potential growth. Challenges lie in maintaining treatment efficacy and navigating regulatory discussions for future developments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.

Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?

AstraZeneca

Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in combination with chemotherapy Clinical data presented at SITC 2023 reinforces COM701 (anti-PVRIG) mediated anti-tumor activity in tumors typically not responding to immunotherapy and initial data suggest PVRL2 as a potential biomarker for COM701 combinations in certain indications Enrollment completed in proof-of-concept study evaluating triple blockade of DNAM-1 axis with COM701 + COM902 (anti-TIGIT) + pembrolizumab in patients with metastatic microsatellite stable colorectal cancer Pre-clinical data presented at SITC 2023 highlights COM503's potential leading edge with an antibody approach to harness IL-18 cytokine biology to treat cancer HOLON, Israel , Nov. 7, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Compugen Reports Third Quarter 2023 Results

COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations mediated clinical benefit in platinum resistant ovarian cancer patients, independent of baseline inflammatory status and was associated with an increase in T cell infiltration to the tumor Metastatic breast cancer adds to previous indications in which COM701 combinations show clinical benefit in tumors typically not responding to immunotherapy PVRL2, the PVRIG ligand, identified as potential predictive biomarker for certain indications Data presented at the SITC conference held on November 1-5, 2023 will be discussed during the Company's Q3 results conference call on Tuesday, November 7, 2023 at 8:30 AM ET HOLON, Israel , Nov. 6, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced data presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held on November 1-5, 2023.

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on November 3, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor site expected to have a favorable therapeutic window compared to engineered cytokines Data to be presented in an oral presentation at SITC, 2023 HOLON, Israel , Oct. 31, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody in an oral presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place 3-5 November 2023, San Diego, CA.

Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer

HOLON, Israel , Oct. 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, before the U.S. financial markets open.

Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023

Gamida Cell Ltd

Kamada

Protalix Biotherapeutics

Taro Pharmaceutical Industries

Teva Pharmaceutical

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

HOLON, Israel , Oct. 3, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.

Compugen to Present at Single Cell Genomics 2023 Meeting

HOLON, Israel , Oct. 2,  2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

HOLON, Israel , Sept. 27, 2023 /PRNewswire/ -- Compugen Ltd.

Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023

HOLON, Israel , Aug. 31, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C.

Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Here is how Compugen (CGEN) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?

Compugen Ltd. (NASDAQ:CGEN ) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Henry Adewoye - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Financial Corp. Asthika Goonewardene - Truist Securities Tony Butler - EF Hutton Operator Ladies and gentlemen, thank you for joining us today.

Compugen Ltd. (CGEN) Q2 2023 Earnings Call Transcript

Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer; initial findings expected by year end  Data from multiple studies planned to be presented by the end of the year:     - New data from metastatic breast cancer study evaluating COM701+ nivolumab       - New translational data and initial biomarker data from platinum resistant ovarian cancer studies evaluating COM701 + nivolumab ± BMS anti-TIGIT      - Longer-term patient follow up from platinum resistant ovarian cancer study evaluating COM701 +  nivolumab + BMS anti-TIGIT      - New data from COM503 lead pre-clinical program HOLON, Israel , August 7, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on key events since the start of 2023.

Compugen Reports Second Quarter 2023 Results

HOLON, Israel , July 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter financial results on Monday, August 7, 2023, before the U.S. financial markets open.

Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023

Patent EP3258951B1, Anti-PVRIG Antibodies and Methods of Use, granted by the European Patent Office covers any anti-PVRIG antibody which activates T cells and/or NK cells for use in the treatment of cancer The opposition division of the European Patent Office ruled to maintain the broad claims of the patent as granted HOLON, Israel , July 17, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the broad claims of Compugen's Anti-PVRIG Antibodies for use in treating cancer patent granted by the European Patent Office, which had been under opposition, have been successfully maintained.

Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

Study builds on clinical benefit reported in heavily pretreated platinum resistant ovarian cancer patients treated with dual and triple combination of COM701 + nivolumab ± BMS-986207 Initial findings expected by the end of 2023 HOLON, ISRAEL , June 22, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen's potential first-in-class anti-PVRIG antibody, with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer.

Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study

COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall response rate 22% (2/9) and disease control rate 44%) with a favorable safety profile Partial response reported in a patient on study treatment for almost 7 months who was previously refractory to standard of care lenvatinib and pembrolizumab Greater peripheral immune activation seen in patients experiencing clinical benefit Data further support potential of COM701 in hard-to-treat tumors including those refractory to immune checkpoint inhibitors HOLON, Israel , June 5, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced data to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, showing that Compugen's COM701 (anti-PVRIG) in triple combination with nivolumab and BMS-986207 (anti-TIGIT) demonstrated preliminary signal of durable anti-tumor activity in patients with recurrent, metastatic MSS endometrial cancer with a favorable safety profile.

Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer

Compugen Ltd. (NASDAQ:CGEN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Henry Adewoye - Chief Medical Officer Eran Ophir - Senior Vice President, Research and Drug Discovery Conference Call Participants Mark Breidenbach - Oppenheimer & Co. Inc. Stephen Willey - Stifel Financial Corp. Asthika Goonewardene - Truist Securities Daina Graybosch - SVB Securities Operator Ladies and gentlemen, thank you for joining us today.

Compugen Ltd. (CGEN) Q1 2023 Earnings Call Transcript

On track to deliver initial findings from studies with the triple blockade of PVRIG, TIGIT and PD-1 in patients with MSS CRC and platinum resistant ovarian cancer by end of 2023 New pre-clinical data presented at CIMT for COM503, a high affinity anti-IL-18BP antibody approach differentiated from cytokine therapeutic approaches Cash balance of $74.3 million with runway through potential key milestones expected into at least end of 2024 Company hosting DNAM-1 axis virtual investor event with KOL Drew Pardoll on Tuesday, May 23, 2023 at 12pm ET, registration on company website HOLON, Israel , May 15, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update on key events since the start of 2023.

Compugen Reports First Quarter 2023 Results

HOLON, Israel , May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will host a virtual DNAM-1 Axis Investor Event on Tuesday, May 23, 2023 at 12:00 pm ET.

Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023

HOLON, Israel , May 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the JMP Securities Life Sciences Conference (virtually), on Tuesday, May 16, 2023 at 9:00 AM ET.

Compugen to Present at the JMP Securities Life Sciences Conference

HOLON, Israel , May 1, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2023 financial results on Monday, May 15, 2023, before the U.S. financial markets open.

Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023

HOLON, Israel , April 27, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 in triple combination with BMS-986207 (anti-TIGIT) and nivolumab in metastatic endometrial cancer at the American Society of Clinical Oncology (ASCO) annual meeting on June 2-6, 2023, in Chicago, Illinois.

Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023

COM503 a potential first-in-class, high affinity anti- IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Compugen plans to file COM503 IND in 2024 HOLON, Israel , April 26, 2023 /PRNewswire/ --  Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present pre-clinical data on its lead pre-clinical asset COM503 in an oral presentation at the 20th CIMT annual meeting, Europe's Cancer Immunotherapy Meeting, on May 3-5, 2023, in Mainz, Germany.

News for Compugen Stock (CGEN)